BIOLOGY
纳安生物
SHANXI BIOLOGICAL TECHNOLOGY CO., LTD
Nanolattix Biotechnology was founded in 2016 by Dr. Zhican Qu, a Ph.D. from Johns Hopkins University in the United States, focusing on innovative anti-cancer biopharmaceuticals and companion diagnostic reagents, especially in the field of antibody drug conjugates (ADC). The company has established the core Nuan biomedical research and development platform, a number of research and development pipelines are steadily advancing. The platform consists of three main components: 1) study of anti-tumor drug targets and screening of specific antibodies; 2) development of anti-cancer ADC drugs in the form of injections and non-injections; and 3) development of diagnostic reagents for tumor therapy and diagnosis.
At present, Nanolattix Biotechnology has established a Nanolattix Bio-Lattix biotechnology platform. It is expected that the first ADC drug T320 will receive clinical approval in China, the United States and Australia in 2024. In the next three years, the company plans to complete the research and development of a number of ADC drugs and promote the marketing of these new drugs and accompanying diagnostic reagents. T320-ADC drugs have the characteristics of precise targeting of a variety of malignant solid tumors, with independent intellectual property rights and patent licenses, and their drug resistance is significant. The success of this project not only fills the gap in the research and development of similar target ADC drugs in China, but also significantly enhances China's international competitiveness in the field of ADC development. At the same time, Nanolattix has built an advanced biomedical technology innovation platform, and projects such as dual anti-B830-ADC and nano-antibody N560-ADC are undergoing preclinical trials to further expand the company's innovative research and development capabilities.
